Quale sarebbe il prezzo per Scilex Holding Company (SCLX)

Il prezzo per Scilex Holding Company (SCLX) è $5.61

Qual è la capitalizzazione di mercato per Scilex Holding Company (SCLX)

La capitalizzazione di mercato per Scilex Holding Company (SCLX) è $47.65M

Scilex Holding Company (SCLX) Rapporto P/S

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Anno	Rapporto P/S	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/S

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/S	Differenza del rapporto P/S	Il paese
Eli Lilly and Company LLY.US	13.95	-	US
Johnson & Johnson JNJ.US	6.41	-	US
AbbVie Inc. ABBV.US	6.85	-	US
Roche Holding AG RO.SW	4.66	-	CH
Merck & Co., Inc. MRK.US	5.05	-	US

Azienda

Rapporto P/S

Differenza del rapporto P/S

Il paese